Fedratinib (SAR302503, TG101348)

Catalog No.S2736

Fedratinib (SAR302503, TG101348) Chemical Structure

Molecular Weight(MW): 524.68

Fedratinib (SAR302503, TG101348) is a selective inhibitor of JAK2 with IC50 of 3 nM in cell-free assays, 35- and 334-fold more selective for JAK2 versus JAK1 and JAK3. Phase 2.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 570 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Colony-forming assay results showing that the Jak2 inhibitor TG101348 reduces CFU-GM colonies generated from mutant fetal liver R2 cells. Results from 4 independent control or mutant fetal livers treated with TG101348 or dimethylsulfoxide (DMSO) are shown (mean ?SD). ***P < .001.

    Blood 2014 123(20), 3175-84. Fedratinib (SAR302503, TG101348) purchased from Selleck.

    Janus kinase (JAK) 1/2 inhibitors increase vesicular stomatitis virus-green fluorescent protein (VSV-GFP) susceptibility in SCC25 cells. Representative photographs of VSV infection in treated cells with and without JAK1/2 inhibitors.

    Cancer Gene Ther 2013 20, 582-9. Fedratinib (SAR302503, TG101348) purchased from Selleck.

  • Claude HAAN Université du Luxembour. Fedratinib (SAR302503, TG101348) purchased from Selleck.

Purity & Quality Control

Choose Selective JAK Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Fedratinib (SAR302503, TG101348) is a selective inhibitor of JAK2 with IC50 of 3 nM in cell-free assays, 35- and 334-fold more selective for JAK2 versus JAK1 and JAK3. Phase 2.
Targets
JAK2 [1]
(Cell-free assay)
JAK2 (V617F) [1]
(Cell-free assay)
FLT3 [1]
(Cell-free assay)
RET [1]
(Cell-free assay)
3 nM 3 nM 15 nM 48 nM
In vitro

TG-101348 also significantly inhibits JAK2 V617F, Flt3, and Ret with IC50 of 3 nM, 15 nM, and 48 nM, respectively. TG101348 has an IC50 ~300-fold higher for the closely related JAK3 and is a less potent inhibitor of the JAK1 and TYK2 family members. TG101348 inhibits proliferation of a human erythroblast leukemia (HEL) cell line that harbors the JAK2V617F mutation, as well as a murine pro-B cell line expressing human JAK2V617F (Ba/F3 JAK2V617F), with IC50 of 305 nM and 270 nM, respectively. TG-101348 also inhibits proliferation of parental Ba/F3 cells to a comparable level, with IC50 of ~420 nM. TG101348 treatment reduces STAT5 phosphorylation at concentrations that parallel the concentrations required to inhibit cell proliferation. TG101348 induces apoptosis in both HEL and Ba/F3 JAK2V617F cells in a dose-dependent manner. TG101348 does not show proapoptotic activity in control normal human dermal fibroblasts at concentrations up to 10 μM, and the antiproliferative IC50 against fibroblasts is >5 μM. [1] TG101348 treatment decreases GATA-1 expression, which is associated with erythroid-skewing of JAK2V617F+ progenitor differentiation, and inhibits STAT5 as well as GATA S310 phosphorylation. [2] TG101348 inhibits the proliferation of HMC-1.1 (KITV560G) cells, with somewhat lower potency than HMC-1.2 (KITD816V, KITV560G) cells, with IC50 of 740 nM and 407 nM, respectively. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
H1975 NVO4[WRbSXCxcITvd4l{KEG|c3H5 M4CxfVAvPS1{IN88US=> M2XrOlEzNTR6IHi= MoLISG1UVw>? M2T1Nolv\HWlZYOgZZBweHSxc3nzJIlvKGKxdHig[I9{\S1iYX7kJJRqdWVvIHTldIVv\GWwdDDtZY5v\XJ? MoTONlU5Pjl{MUC=
H1650 MVfBdI9xfG:|aYOgRZN{[Xl? NY\tNoltOC53LUKg{txO NELwbXIyOi12ODDo MXzEUXNQ MkT0bY5lfWOnczDhdI9xfG:|aYOgbY4h[m:2aDDkc5NmNSCjbnSgeIlu\S1iZHXw[Y5l\W62IH3hco5meg>? MUeyOVg3QTJzMB?=
H1975 MYPGeY5kfGmxbjDBd5NigQ>? MmXtNE4zPS1zIN88US=> NYe3cItSOjRiaB?= MoKzSG1UVw>? NGDGdYhqdmirYnn0d{BmgHC{ZYPzbY9vKG:oIHHwc5B1d3Orcz3y[YxifGWmIIDyc5RmcW5iQnPsMXhNNCCEY3ytNkwhe3W{dnn2bY4tKFiLQWC= MYmyOVg3QTJzMB?=
H1650 NXPRdXY2TnWwY4Tpc44hSXO|YYm= NXXB[nVvOC5{NT2xJO69VQ>? M1fzUlI1KGh? Mn7WSG1UVw>? NVrKRZBlcW6qaXLpeJMh\XiycnXzd4lwdiCxZjDhdI9xfG:|aYOtdoVt[XSnZDDwdo91\WmwIFLjcE1ZVCxiQnPsMVItKHO3co\peolvNCC[SVHQ NWG1NIRoOjV6NkmyNVA>
H1975 M1Xvfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHPNUDPxE1? MXm0PEBp MVjEUXNQ NXXJVZZbe2Wwc3n0bZpmeyClZXzsd{B1dyC2aHWgZ5l1d3SxeHnjbZR6KG:oIHXycI91cW6rYh?= NWXFTpJDOjV6NkmyNVA>
H1650 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrDNUDPxE1? MWe0PEBp NV3meZJ2TE2VTx?= NUXjZXd{e2Wwc3n0bZpmeyClZXzsd{B1dyC2aHWgZ5l1d3SxeHnjbZR6KG:oIHXycI91cW6rYh?= MkC2NlU5Pjl{MUC=
CD4+ T M2\MT2Z2dmO2aX;uJGF{e2G7 M1n5VlAvODFvMTFOwG0> NYOyUYlXPDhiaB?= MWTEUXNQ M1jkOJJm\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBt\X[nbIOgc4YhUkGNMjDhcoQhW1SDVERCpC=> NGHCN4UzPTV5MkWzOS=>
Caco-2  MYrGeY5kfGmxbjDBd5NigQ>? MlrxNE0yOjBizszN M4fC[FchdWmw MWHpcohq[mm2czD0bIlidWmwZTD1dJRic2Vid3n0bEBidiCLQ{WwxsBw\iB{LkJCpOK2VQ>? M3uwcFI2ODZ|Nkey
Caco-2  MljhSpVv[3Srb36gRZN{[Xl? NVTJOZZwOTBxNUCvNVAxKM7:TR?= MUCyJIg> MV7k[YNz\WG|ZYOgeIhmKG[udYigc4YhYzOKXYTobYFucW6nIHHjdo9{eyC2aHWgcY9vd2yjeXXyJJdqfGhiSVO1NEBw\iB4LkZCpO69VQ>? MUCyOVA3OzZ5Mh?=
HEK293 MSR  NUnJT3BJTnWwY4Tpc44hSXO|YYm= M3fKPVAuOTBizszN M4TOXlchdWmw MlLObY5pcWKrdIOgbHRJXFJ{IIfpeIgh[W5iSVO1NOKhd2ZiMT6yxsDDvU1? Mnu4NlUxPjN4N{K=
MedB-1 MYXGeY5kfGmxbjDBd5NigQ>? M1PnOlEwOiEQvF2= NH7RRXgzPCCq M3\sboRm[3KnYYPld{BUXEGWNjDwbI9{eGixconsZZRqd25iY3;uZ4VvfHKjdHnvckBl\XCnbnTlcpRtgQ>? MnjGNlQ6Pzd4Nki=
U2940 NWPkc4lHTnWwY4Tpc44hSXO|YYm= M4nSS|EwOiEQvF2= M3v0RlI1KGh? MXLk[YNz\WG|ZYOgV3RCXDZicHjvd5Bpd3K7bHH0bY9vKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk> NF3DcVEzPDl5N{[2PC=>
K1106 Mnu2SpVv[3Srb36gRZN{[Xl? NFn0RpIyNzJizszN MVSyOEBp Mkfs[IVkemWjc3XzJHNVSVR4IIDoc5NxcG:{eXzheIlwdiClb37j[Y51emG2aX;uJIRmeGWwZHXueIx6 Ml[wNlQ6Pzd4Nki=
K562 NF7McJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XHN|AuOSEQvF2= NHTxco44OiCq NHzZNGNqdmirYnn0d{BMPTZ{IHPlcIwheHKxbHnm[ZJifGmxbjDheEBpcWeqIHPvcoNmdnS{YYTpc44> MVuyOFc4PTNyOB?=
MDA-MB-468  NIjKSm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HxS|MhyrWP NYS0eWJvPDhiaB?= M3L2WoVvcGGwY3XkJJNq[mOuNjDpcoR2[2WmIHzvd5Mhd2ZiY3XscEB3cWGkaXzpeJnDqA>? NVmzd|BQOjR4NkK4NVg>
MDA-MB-468 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjiT4kxNTRizszN NWfpO5VJPDhiaB?= MV\y[ZN2dHS|IIPp[45q\mmlYX70JIxwe3Nib3[geoli[mmuaYT5JINwdXCjcnXkJJRwKFKLLVLQTUBidG:wZR?= MWOyOFY3OjhzOB?=
L428 NWO0bXdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWWwMVUh|ryP NYW0WGlIPDhiaB?= MknCbY5pcWKrdIOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueR?= M4TuTlI1PjFyOEK3
KMH2 M4TJSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX2wMVUh|ryP NY\PUmFWPDhiaB?= MYfpcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7 MkHnNlQ3OTB6Mke=
L1236 NYD6[HdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYGwMVUh|ryP NHTHc4E1QCCq M3XkTYlvcGmkaYTzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bIm= NUXuXnhFOjR4MUC4Nlc>
SUPHD1 NGfzTXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfTfWhiOC13IN88US=> Mn:5OFghcA>? M3\nNYlvcGmkaYTzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bIm= M1XHXFI1PjFyOEK3
HDLM2 NWj0U2Y1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPQZ5gxNTVizszN NFW3fII1QCCq MWPpcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7 M13lO|I1PjFyOEK3
K1106P M4DMbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLDNE02KM7:TR?= M1fLZ|Q5KGh? NFO5enZqdmirYnn0d{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5 MUOyOFYyODh{Nx?=
L428 NEC2TpdCeG:ydH;zbZMhSXO|YYm= NFrl[okxNzBwNkK1M|EvOjVizszN NVfVcGhxPDhiaB?= NFuzSVVqdmS3Y3XzJJRp\SCjcH;weI9{cXQEoB?= M{L3OVI1PjFyOEK3
KMH2 MWrBdI9xfG:|aYOgRZN{[Xl? NIfBdXUxNzBwNkK1M|EvOjVizszN NHS1V5Q1QCCq NW[5dJc5cW6mdXPld{B1cGViYYDvdJRwe2m|wrC= MnnXNlQ3OTB6Mke=
L1236 MV;BdI9xfG:|aYOgRZN{[Xl? NF63fYYxNzBwNkK1M|EvOjVizszN M1;QbVQ5KGh? NGjDellqdmS3Y3XzJJRp\SCjcH;weI9{cXQEoB?= M{jGXVI1PjFyOEK3
SUPHD1 M3f3ZmFxd3C2b4Ppd{BCe3OjeR?= NF\QOJMxNzBwNkK1M|EvOjVizszN NIj1SIw1QCCq NXjqcVNUcW6mdXPld{B1cGViYYDvdJRwe2m|wrC= NYr2fpU{OjR4MUC4Nlc>
HDLM2 M1HWWmFxd3C2b4Ppd{BCe3OjeR?= NFrDO2kxNzBwNkK1M|EvOjVizszN Mm\ZOFghcA>? MknnbY5lfWOnczD0bIUh[XCxcITvd4l{yqB? NXjG[IFYOjR4MUC4Nlc>
K1106P NIjYPI1CeG:ydH;zbZMhSXO|YYm= MkXVNE8xNjZ{NT:xMlI2KM7:TR?= M3vwb|Q5KGh? MmG0bY5lfWOnczD0bIUh[XCxcITvd4l{yqB? NIfHSHczPDZzMEiyOy=>
L428 M1nkbWZ2dmO2aX;uJGF{e2G7 M4DobFAuPSEQvF2= MVyyOEBp MVzpcohq[mm2czDKRWszN1OWQWSgd4lodmGuaX7n NV;zOoE1OjR4MUC4Nlc>
KMH2 MUfGeY5kfGmxbjDBd5NigQ>? MV2wMVUh|ryP NIr1cGIzPCCq NGP0UVFqdmirYnn0d{BLSUt{L2PURXQhe2mpbnHsbY5o MWOyOFYyODh{Nx?=
L1236 MmTVSpVv[3Srb36gRZN{[Xl? M1jUWlAuPSEQvF2= MYSyOEBp M{jxW4lvcGmkaYTzJGpCUzJxU2TBWEB{cWewYXzpcoc> M1nDR|I1PjFyOEK3
SUPHD1 NX\0S2tiTnWwY4Tpc44hSXO|YYm= MXywMVUh|ryP NFuxN3czPCCq NH;Be3lqdmirYnn0d{BLSUt{L2PURXQhe2mpbnHsbY5o Ml3XNlQ3OTB6Mke=
HDLM2 MmjYSpVv[3Srb36gRZN{[Xl? M1\ZTVAuPSEQvF2= M1fXRlI1KGh? NVv0b41XcW6qaXLpeJMhUkGNMj;TWGFVKHOrZ37hcIlv\w>? NVPPR29rOjR4MUC4Nlc>
K1106P M{TZU2Z2dmO2aX;uJGF{e2G7 NH7OZ5MxNTVizszN M2LGRVI1KGh? MkHxbY5pcWKrdIOgTmFMOi:VVFHUJJNq\26jbHnu[y=> MnPMNlQ3OTB6Mke=
MM.1S  NE[zfYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TiWmlEPTB;MT2zJO69VQ>? MViyOFU5PDFyMR?=
TpoR JAK2 WT MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHPZY1KSzVyPUGuOEApOS5|4pETNU42MSEQvF2= NGTX[VkzPDJ3MUe5NC=>
TpoR JAK2 V617F NFT2ZotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjrTWM2OD1yLkigLFAvP+LCk{CuPUkh|ryP MXuyOFI2OTd7MB?=
TpoR W515L M3fS[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLxenhKSzVyPUCuPEApOC554pETNU4xMSEQvF2= MmLZNlQzPTF5OUC=
Bcr-abl NX;BWXFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXVTopKSzVyPUKuO{ApOi5{4pETN{4{MSEQvF2= M1m0V|I1OjVzN{mw
JAK2 TW NXnLUJBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTYb2lKSzVyPUGuPEApOS534pETNk4{MSEQvF2= M{S5V|I1OjVzN{mw
JAK2 V617F MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrhTpZKSzVyPUCuOkApOC544pETNE44MSEQvF2= MkXZNlQzPTF5OUC=
MedB-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4riTVQh|ryP M1XUe|I1NzR6L{eyJIg> MWXEUXNQ M1HHOolvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWg[IVx\W6mZX70cJk> NWPlPXFROjN6NUKzOlY>
K1106 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIf1T441KM7:TR?= MmjHNlQwPDhxN{KgbC=> MnruSG1UVw>? NELMeXVqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lJIRmeGWwZHXueIx6 NVH0blZNOjN6NUKzOlY>
U2940 NWDVTJpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHUbWI1KM7:TR?= MXOyOE81QC95MjDo Mo\wSG1UVw>? NUe1TXNucW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBl\XCnbnTlcpRtgQ>? MoDRNlM5PTJ|Nk[=
FE-PD NUDqdphQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXYNE4xPjNvNDFOwG0> M{fFNGlEPTB;OT61JO69VSxiaX7obYJqfHNiY3XscEBoem:5dHig[I9{\SCmZYDlcoRmdnSueR?= M4PV[FI{Ozd{Nk[5
HEL MofOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIKzeWExNjB4Mz20JO69VQ>? NF7hZ3BKSzVyPUGuOUDPxE1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIRwe2ViZHXw[Y5l\W62bIm= NXvodlFjOjN|N{K2Olk>
K-562 MoHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml33NE4xPjNvNDFOwG0> NHX0XXZKSzVyPUKuOUDPxE1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIRwe2ViZHXw[Y5l\W62bIm= NF3HXVEzOzN5Mk[2PS=>
L-82 Ml;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUi3[5NwOC5yNkOtOEDPxE1? M3P1T2lEPTB;MD65PEDPxE1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIRwe2ViZHXw[Y5l\W62bIm= M3v3bVI{Ozd{Nk[5
MAC-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7v[XExNjB4Mz20JO69VQ>? M17k[GlEPTB;MD61NkDPxE1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIRwe2ViZHXw[Y5l\W62bIm= MW[yN|M4OjZ4OR?=
MAC-2A NYLkflZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrrWYtlOC5yNkOtOEDPxE1? M3XuOmlEPTB;MD62PUDPxE1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIRwe2ViZHXw[Y5l\W62bIm= MoTLNlM{PzJ4Nkm=
MAC-2B MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvqZWsxNjB4Mz20JO69VQ>? NX;pUW5[UUN3ME2wMlU1KM7:TTygbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NIjwbGkzOzN5Mk[2PS=>
MY-LA M{P4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfjNE4xPjNvNDFOwG0> NF3aWHRKSzVyPUKuNUDPxE1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIRwe2ViZHXw[Y5l\W62bIm= MoLBNlM{PzJ4Nkm=
NC-NC M3jEd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PxWVAvODZ|LUSg{txO MkTlTWM2OD1zLkCg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDkc5NmKGSncHXu[IVvfGy7 MXeyN|M4OjZ4OR?=
SE-AX NGHDXpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILyRZMxNjB4Mz20JO69VQ>? MVHJR|UxRTFwNTFOwG0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHTvd4Uh\GWyZX7k[Y51dHl? M3LyXFI{Ozd{Nk[5
SR-786 NF6xdVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HDSlAvODZ|LUSg{txO MYfJR|UxRTRwNjFOwG0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHTvd4Uh\GWyZX7k[Y51dHl? MXqyN|M4OjZ4OR?=
M-MOK  NYXaU2o4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfHWVgzPSEEtV5CpC=> NWiwSIlJOjRxNEivO|IhcA>? NF3TXZhFVVOR NH3ZdnZqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lJIRmeGWwZHXueIx6 NHy1Z2ozOTh3M{G1Oy=>
HEL M2DD[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTNyNTDuUS=> MWKxPFM6PDV3NB?=
Ba/F3 JAK2V617F MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrPTWM2OD1{N{Cgcm0> NEnVR4YyQDN7NEW1OC=>

... Click to View More Cell Line Experimental Data

In vivo TG101348 has potential for efficacious treatment of JAK2V617F-associated myeloproliferative diseases (MPD). In treated animals, there is a statistically significant reduction in hematocrit and leukocyte count, a dose-dependent reduction/elimination of extramedullary hematopoiesis, and, at least in some instances, evidence for attenuation of myelofibrosis, correlated with surrogate endpoints, including reduction/elimination of JAK2V617F disease burden, suppression of endogenous erythroid colony formation, and in vivo inhibition of JAK-STAT signal transduction. There are no apparent toxicities and no effect on T cell number. [1] Oral administration of TG101348 (120 mg/kg) significantly inhibits PV progenitor erythroid differentiation in vivo. [2]

Protocol

Kinase Assay:[1]
+ Expand

Cell-free Kinase Activity Assays:

IC50 values for TG101348 are determined commercially using the InVitrogen kinase profiling service for a 223 kinase screen that included JAK2 and JAK2V617F or Carna Biosciences for the screen of all Janus kinase family members including JAK1 and Tyk2. ATP concentration is set to approximately the Km value for each kinase.
Cell Research:[1]
+ Expand
  • Cell lines: EpoBa/F3 JAK2V617F, Ba/F3p210, HEL, and K562
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method: Approximately 2 × 103 cells are plated into microtiter-plate wells in 100 μL RPMI-1640 growth media with indicated concentrations of inhibitor. Following 72 hours incubation with TG101348, 50 μL of XTT dye are added to each well and incubated for 4 hours in a CO2 incubator. The colored formazan product is measured by spectrophotometry at 450 nm with correction at 650 nm. The concentration in which 50% of the effect (i.e., inhibition of proliferation) is observed (IC50) is determined using the GraphPad Prism 4.0 software. All experiments are performed in triplicate, and the results are normalized to growth of untreated cells. Induction of apoptosis of EpoBa/F3 JAK2V617F, Ba/F3p210, HEL, and K562 cells is determined by DNA fragmentation with DMSO and increasing concentrations of TG101348.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: C57BL/6 mice injected intravenously with whole bone marrow expressing JAK2V617F
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~120 mg/kg
  • Administration: Oral gavage twice daily (b.i.d.)
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (190.59 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 524.68
Formula

C27H36N6O3S

CAS No. 936091-26-8
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01836705 Completed Neoplasm Malignant Sanofi May 2013 Phase 1
NCT01762462 Completed Hepatic Impairment Sanofi December 2012 Phase 1
NCT01763190 Completed Renal Impairment Sanofi November 2012 Phase 1
NCT01692366 Completed Myelofibrosis Sanofi November 2012 Phase 2
NCT01585623 Completed Solid Tumor Sanofi June 2012 Phase 1
NCT01523171 Completed Hematopoietic Neoplasm Sanofi April 2012 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

JAK Signaling Pathway Map

JAK Inhibitors with Unique Features

Related JAK Products

Tags: buy Fedratinib (SAR302503, TG101348) | Fedratinib (SAR302503, TG101348) supplier | purchase Fedratinib (SAR302503, TG101348) | Fedratinib (SAR302503, TG101348) cost | Fedratinib (SAR302503, TG101348) manufacturer | order Fedratinib (SAR302503, TG101348) | Fedratinib (SAR302503, TG101348) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID